Every 10-Q that Cingulate Inc. Warrants (CINGW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CINGW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CINGW filings page.
Cingulate Inc., a pre‑revenue biopharmaceutical company focused on ADHD and anxiety therapies, reported a net loss of $5.9 million for the quarter and $15.2 million for the six months ended June 30 2026, larger than the prior‑year periods. Operating cash outflow was $12.8 million in the first half.
Cash and cash equivalents increased to $28.4 million from $11.0 million at year‑end 2025, driven by a $12.0 million private placement, at‑the‑market issuances and equity sales under a Lincoln Park purchase agreement. Total liabilities fell to $9.6 million, primarily as a prior Streeterville note was extinguished and the Avondale note was partially repaid or exchanged into equity.
The FDA issued a Complete Response Letter for lead ADHD candidate CTx‑1301, requesting additional CMC information but not raising clinical safety or efficacy concerns. Management is working with its CDMO to support NDA resubmission. The company discloses substantial doubt about its ability to continue as a going concern despite current liquidity, and expects to seek additional capital. A new U.S. patent issued in June 2026 protects CTx‑1301 through December 2042.
Cingulate Inc. reported a larger net loss for the quarter ended March 31, 2026 as it funds late‑stage ADHD development and commercial preparation. Net loss widened to $9.3 million from $3.9 million a year earlier, with general and administrative costs rising sharply to $5.7 million as the company ramped pre‑commercialization spending for lead candidate CTx‑1301.
Research and development expenses were stable at about $2.2 million, reflecting a shift from clinical operations toward manufacturing and regulatory work ahead of potential approval. Cash and cash equivalents increased to $25.9 million, driven by equity raises, including a ~$12 million private placement, ATM sales and an equity line with Lincoln Park.
The company ended the quarter with $18.9 million of stockholders’ equity and $12.0 million in total liabilities, including a $6.1 million Avondale promissory note. Management believes current cash can fund operations into early 2027 but discloses substantial doubt about its ability to continue as a going concern without additional capital and successful FDA approval and commercialization of CTx‑1301.
Cingulate Inc. reported interim financials showing significant operating losses and active equity financings. The company recorded operating loss of $8,356,009 for the six-month period and a loss before income taxes of $(4,788,735) for the three-month period, with an accumulated deficit of approximately $117.1 million. Cash-raising activity included at-the-market sales and Lincoln Park purchase agreements providing net proceeds (examples: $2,599,099 under the ATM during six months ended June 30, 2025 and $3,513,236 under the Original LP Purchase Agreement during the same period). The company disclosed a $5.48 million unsecured promissory note with a 9% coupon and material default penalty mechanics. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year and noted efforts to seek additional equity, debt, or strategic transactions. The financial statements are unaudited interim results prepared on a going concern basis.